In conclusion, our results demonstrate that hucMSC-Ex relieves IBD by targeting ACSL4 with miR-129-5p to reduce LPO levels and ferroptosis, reducing intestinal inflammation and repairing the damage. This evidence concerns the gene ACSL4 and inflammatory bowel disease.